Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
AddLife AB
of SWEDEN
(2020
sales of 5.27 billion Swedish Kronor [US$611.12 million]
of which 61%
was LabTech),
Genus plc
of UNITED KINGDOM
(£551.40 million [US$757.42 million]
of which 54%
was Operating Genus PIC), and
GW Pharmaceuticals PLC
which is
also
based in UNITED KINGDOM
(£407.91 million [US$560.32 million]
of which 100%
was Novel Therapeutics).
Sales Analysis.
Galapagos NV reported sales of 530.26 million Euro (US$629.76 million)
for the
year ending
December of 2020.
This
represents
a
sharp
decrease of 40.8%
versus 2019, when the company's sales were 895.89 million Euro.